Maximizing impact: the power of early HPV vaccination for long-term protection―lessons from a systematic review and meta-regression analysis
Journal of Public Health · 2026
DOI: 10.1093/pubmed/fdag002 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Public Health, 2026. Verfasst von Adoración Navarro-Torné und 5 weiteren Autor:innen. Beteiligte Einrichtung: Viral Non-Respiratory, Vaccines and Infectious Disease Epidemiology, GSK, Tres Cantos 28760, Spain. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Uterine Cervical Neoplasms, Papillomavirus Infections. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Background
This systematic review and meta-regression analysis assessed the impact of human papillomavirus 16/18 (HPV16/18)-AS04 vaccine (Cervarix®) on advanced cervical lesions, including grade 3 cervical intraepithelial neoplasia or worse (CIN3, CIN3+), or cervical cancer, highlighting age-at-vaccination–dependent vaccine efficacy and effectiveness.
Methods
Studies reporting HPV16/18-AS04 vaccine efficacy or effectiveness were included with an intervention group receiving HPV16/18-AS04 vaccine and comparator group receiving placebo, another vaccine or being unvaccinated. Of 53 articles identified, nine were selected. Meta-analysis and meta-regression models with random effects and data-driven model selection determined vaccine effects (VEs) and impactful covariates.
Results
HPV16/18-AS04 vaccine effectively prevented advanced cervical premalignant lesions and cancer in adolescent girls and women vaccinated at 12–25 years. Combined randomized controlled trials and observational studies VEs on CIN3+ ranged between 76.78% (95% CI 28.15–92.49) for HPV16/18 and 56.19% (95% CI 24.76–74.49) irrespective of HPV type. Vaccine effectiveness was greatest in those vaccinated at the youngest ages.
Conclusions
HPV16/18-AS04 vaccine provides long-term protection against cervical premalignant lesions and cervical cancer in both controlled and real-world settings, particularly when administered at younger ages. The evidence urges policymakers and the community to ensure HPV vaccination begins at the youngest recommended ages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Viral Non-Respiratory, Vaccines and Infectious Disease Epidemiology, GSK, Tres Cantos 28760, Spain.
- Real-World Biostatistics, GSK, Wavre 1300, Belgium.
- Statistics, GSK, Rixensart 1330, Belgium.
- A&N Immugen, Egloffstein 91349, Germany.
- Viral Non-Respiratory, Vaccines and Infectious Disease Epidemiology, GSK, Rockville, MD 20850, USA.
- Global Medical Lead, GSK, Wavre 1300, Belgium.
ORCID-Profile: Emmanuel Aris, Andrea Callegaro, Huifeng Yun
Förderung
- GSK
Zitieren
APA
Navarro-Torné, A., Aris, E., Callegaro, A., Benninghoff, B., Yun, H., & Vetter, V. (2026). Maximizing impact: the power of early HPV vaccination for long-term protection―lessons from a systematic review and meta-regression analysis. Journal of Public Health. https://doi.org/10.1093/pubmed/fdag002
Vancouver
Navarro-Torné A, Aris E, Callegaro A, Benninghoff B, Yun H, Vetter V. Maximizing impact: the power of early HPV vaccination for long-term protection―lessons from a systematic review and meta-regression analysis. Journal of Public Health. 2026. doi:10.1093/pubmed/fdag002
BibTeX
@article{NavarroTorn2026,
author = {Navarro-Torné, Adoración and Aris, Emmanuel and Callegaro, Andrea and Benninghoff, Bernd and Yun, Huifeng and Vetter, Volker},
title = {Maximizing impact: the power of early HPV vaccination for long-term protection―lessons from a systematic review and meta-regression analysis},
journal = {Journal of Public Health},
year = {2026},
doi = {10.1093/pubmed/fdag002}
}
EUVIMED